Abstract
Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
CNS & Neurological Disorders - Drug Targets
Title:Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders
Volume: 12 Issue: 5
Author(s): Shafiqur Rahman
Affiliation:
Keywords: Drug addiction, nicotinic receptors, nicotine addiction, alcoholism, cocaine, opioids, pharmacotherapy, drug development.
Abstract: Drug addiction is a chronic neuropsychiatric disorder which is characterized by a compulsion to take drugs and loss of control in limiting intake. The worldwide impact of drug addiction on morbidity and mortality is very high. Evidence from preclinical and clinical studies suggests that brain nicotinic acetylcholine receptors (nAChRs), play a critical role in various addictive disorders, including nicotine addiction and alcoholism. Thus, there is an increasing impetus in developing new therapeutics for addictive disorders by targeting brain nAChRs. This review highlights the important preclinical findings involving nAChR ligands in regulating nicotine, alcohol and other addictive drug-induced neurobiological changes in animal models and humans. A number of partial agonists or antagonists targeting nAChRs have shown therapeutic benefit in nicotine addiction and alcohol use disorders are also discussed. Furthermore, the role of nAChRs in other addictive disorders is reviewed. Overall, novel pharmacological agents that target brain nAChRs for future drug development are discussed.
Export Options
About this article
Cite this article as:
Rahman Shafiqur, Nicotinic Receptors as Therapeutic Targets for Drug Addictive Disorders, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050011
DOI https://dx.doi.org/10.2174/1871527311312050011 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Cocaine-induced Changes in the Expression of NMDA Receptor Subunits
Current Neuropharmacology Achieving Detumescence of Ischemic Priapism with Intra-Cavernosal Injection of entanyl: An Unexpected Outcome of Miscommunication Error
Current Drug Safety Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy
Current Medicinal Chemistry Current Therapeutic Options for Alzheimers Disease
Current Genomics Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Proline-Rich Domain and the Microtubule Binding Domain of Protein Tau Acting as RNA Binding Domains
Protein & Peptide Letters Metabotropic Glutamate Receptors in the Control of Mood Disorders
CNS & Neurological Disorders - Drug Targets Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Proteomic analysis of a <i>hom</i>-disrupted, cephamycin C overproducing <i>Streptomyces clavuligerus</i>
Protein & Peptide Letters Pharmacophore and 3D-QSAR Characterization of Thieno[3,2-d] pyrimidine-6-carboxamides as SIRT-2 Inhibitors
Letters in Drug Design & Discovery Detection of Mild Cognitive Impairment Based on Virtual Reality: A Scoping Review
Current Alzheimer Research Marinobufagenin in Urine: A Potential Marker of Predisposition to Ethanol and a Target for Spironolactone
Current Hypertension Reviews Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Critical Role of Computer Simulations in Drug Discovery and Development
Current Topics in Medicinal Chemistry Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Recent Advances in the Development of Broad-Spectrum Antiprotozoal Agents
Current Medicinal Chemistry A Pharmacological Review of Five Widely Used Traditional Medicinal Plants for Sedative-Hypnotic Effects in Bangladesh
Current Traditional Medicine Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors
Current Pharmaceutical Design